AMP-Activated protein kinase and metabolic control

Handbook of Experimental Pharmacology

Volumn 203, Issue , 2015, Pages 303-330

  Viollet, Benoit ^a,b,c   Andreelli, Fabrizio ^a,b,c,d  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

AMP activated protein kinase; Diabetes; Energy balance; Obesity; Therapeutic strategy

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; METFORMIN; RESVERATROL;

ARTICLE; CALORIC RESTRICTION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME REGULATION; ENZYME STRUCTURE; EXERCISE; HEART MUSCLE ISCHEMIA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER MEMBRANE; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATIENT CARE; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; THERAPY EFFECT; TREATMENT INDICATION;

EID: 84924080963     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-17214-4_13     Document Type: Article

References (191)

1. Alberti KG, Zimmet PZ (1998) New diagnostic criteria and classification of diabetes-again? Diabet Med15:535-536.
2. Andersson U, Filipsson K et al (2004) AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem279:12005-12008.
3. Andreelli F, Foretz M et al (2006) Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology147:2432-2441.
4. Anthonsen MW, Ronnstrand L et al (1998) Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem273:215-221.
5. Assifi MM, Suchankova G et al (2005) AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab 289:E794-E800.
6. Banerjee RR, Rangwala SM et al (2004) Regulation of fasted blood glucose by resistin. Science303:1195-1198.
7. Banks AS, Kon N et al (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab8:333-341.
8. Barnes BR, Marklund S et al (2004) The 50-AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J Biol Chem279:38441-38447.
9. Baur JA, Pearson KJ et al (2006) Resveratrol improves health and survival of mice on a highcalorie diet. Nature444:337-342.
10. Bergeron R, Russell RR 3rd et al (1999) Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol276:E938-E944.
11. Bergeron R, Previs SF et al (2001a) Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes50:1076-1082.
12. Bergeron R, Ren JM et al (2001b) Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab281:E1340-E1346.
13. Boon H, Bosselaar M et al (2008) Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia 51:1893-1900.
14. Bordone L, Motta MC et al (2006) Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol4:e31.
15. Bruce CR, Mertz VA et al (2005) The stimulatory effect of globular adiponectin on insulinstimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes54:3154-3160.
16. Buhl ES, Jessen N et al (2002) Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes51:2199-2206.
17. Butler AE, Janson J et al (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes52:102-110.
18. Canto C, Gerhart-Hines Z et al (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature458:1056-1060.
19. Canto C, Jiang LQ et al (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab11:213-219.
20. Carattino MD, Edinger RS et al (2005) Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells. J Biol Chem280:17608-17616.
21. Carey DG, Cowin GJ et al (2002) Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res10:1008-1015.
22. Carey AL, Steinberg GR et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes55:2688-2697.
23. Chen ZP, Mitchelhill KI et al (1999) AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett443:285-289.
24. Chen ZP, McConell GK et al (2000) AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab279:E1202-E1206.
25. Chen Z, Peng IC et al (2009) AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res104:496-505.
26. Clarke PR, Hardie DG (1990) Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J9:2439-2446.
27. Collins QF, Liu HY et al (2007) Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 50-AMP-activated protein kinase. J Biol Chem282:30143-30149.
28. Cool B, Zinker B et al (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab3:403-416.
29. Corton JM, Gillespie JG et al (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558-565.
30. daSilva Xavier G, Leclerc I et al (2003) Role for AMP-activated protein kinase in glucosestimulated insulin secretion and preproinsulin gene expression. Biochem J371:761-774.
31. Dasgupta B, Milbrandt J (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA104:7217-7222.
32. Daval M, Diot-Dupuy F et al (2005) Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem280:25250-25257.
33. Davis BJ, Xie Z et al (2006) Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55:496-505.
34. De Fronzo RA, Tripathy D (2009) Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32(Suppl2):S157-S163.
35. Donath MY, Ehses JA et al (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54(Suppl2):S108-S113.
36. Dreyer HC, Drummond MJ et al (2008) Resistance exercise increases human skeletal muscle AS160/TBC1D4 phosphorylation in association with enhanced leg glucose uptake during postexercise recovery. J Appl Physiol105:1967-1974.
37. Dyck JR, Lopaschuk GD (2006) AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol574:95-112.
38. Eckel RH, Grundy SM et al (2005) The metabolic syndrome. Lancet365:1415-1428.
39. El-Assaad W, Buteau J et al (2003) Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology144:4154-4163.
40. Eto K, Yamashita T et al (2002) Genetic manipulations of fatty acid metabolism in beta-cells are associated with dysregulated insulin secretion. Diabetes 51(Suppl3):S414-S420.
41. Evans AM, Mustard KJ et al (2005) Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to calcium signaling in O2-sensing cells? J Biol Chem280:41504-41511.
42. Febbraio MA, Pedersen BK (2005) Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev33:114-119.
43. Fisher JS, Gao J et al (2002) Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab282:E18-E23.
44. Fonseca VA (2009) Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32(Suppl2):S151-S156.
45. Foretz M, Carling D et al (1998) AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem273:14767-14771.
46. Foretz M, Ancellin N et al (2005) Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes54:1331-1339.
47. Fraser SA, Mount PF et al (2003) Inhibition of the Na-K-2Cl cotransporter by novel interaction with the metabolic sensor AMP-activated protein kinase. J Am Soc Nephrol14:545A.
48. Fryer LG, Parbu-Patel A et al (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem277:25226-25232.
49. Fujii N, Ho RC et al (2008) Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes57:2958-2966.
50. Garton AJ, Yeaman SJ (1990) Identification and role of the basal phosphorylation site on hormone-sensitive lipase. Eur J Biochem191:245-250.
51. Garton AJ, Campbell DG et al (1989) Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur J Biochem 179:249-254.
52. Gledhill JR, Montgomery MG et al (2007) Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci USA104:13632-13637.
53. Glund S, Deshmukh A et al (2007) Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes56:1630-1637.
54. Glund S, Treebak JT et al (2009) Role of adenosine 5'-monophosphate-activated protein kinase in interleukin-6 release from isolated mouse skeletal muscle. Endocrinology150:600-606.
55. Hammer S, Snel M et al (2008) Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol52:1006-1012.
56. Hayashi T, Hirshman MF et al (1998) Evidence for 50 AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes47:1369-1373.
57. Higa M, Zhou YT et al (1999) Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA96:11513-11518.
58. Holmes BF, Kurth-Kraczek EJ et al (1999) Chronic activation of 50-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol87:1990-1995.
59. Holmes BF, Lang DB et al (2004) AMP kinase is not required for the GLUT4 response to exercise and denervation in skeletal muscle. Am J Physiol Endocrinol Metab287:E739-E743.
60. Hou X, Xu S et al (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMPactivated protein kinase. J Biol Chem283:20015-20026.
61. Howitz KT, Bitterman KJ et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature425:191-196.
62. Iglesias MA, Ye JM et al (2002) AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes51:2886-2894.
63. Jager S, Handschin C et al (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA104:12017-12022.
64. Jazet IM, Schaart G et al (2008) Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. Diabetologia51:309-319.
65. Jorgensen SB, Wojtaszewski JF et al (2005) Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J19:1146-1148.
66. Kahn SE, Hull RL et al (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature444:840-846.
67. Kaiser N, Leibowitz G et al (2003) Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab16:5-22.
68. Kamohara S, Burcelin R et al (1997) Acute stimulation of glucose metabolism in mice by leptin treatment. Nature389:374-377.
69. Katsuki A, Sumida Y et al (2003) Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care26:2341-2344.
70. Kefas BA, Cai Y et al (2003a) AMP-activated protein kinase can induce apoptosis of insulinproducing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol30:151-161.
71. Kefas BA, Heimberg H et al (2003b) AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia46:250-254.
72. Kelly M, Keller C et al (2004) AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun320:449-454.
73. Kim MS, Park JY et al (2004) Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med10:727-733.
74. Kim WH, Lee JW et al (2007) AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. Cell Signal19:791-805.
75. Knowler WC, Barrett-Connor E et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med346:393-403.
76. Koistinen HA, Galuska D et al (2003) 5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes52:1066-1072.
77. Kola B, Hubina E et al (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196-25201.
78. Koo SH, Flechner L et al (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature437:1109-1111.
79. Kubota N, Terauchi Y et al (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem277:25863-25866.
80. Kurth-Kraczek EJ, Hirshman MF et al (1999) 50 AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes48:1667-1671.
81. Lagouge M, Argmann C et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell127:1109-1122.
82. Lan F, Cacicedo JM et al (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem283:27628-27635.
83. Larson-Meyer DE, Heilbronn LK et al (2006) Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care29:1337-1344.
84. Lau KS, Grange RW et al (2000) nNOS and eNOS modulate cGMP formation and vascular response in contracting fast-twitch skeletal muscle. Physiol Genomics2:21-27.
85. Leclerc I, Kahn A et al (1998) The 50-AMP-activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex. FEBS Lett431:180-184.
86. Leclerc I, Lenzner C et al (2001) Hepatocyte nuclear factor-4alpha involved in type 1 maturityonset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes50:1515-1521.
87. Leclerc I, Woltersdorf WW et al (2004) Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab286:E1023-E1031.
88. Lee WJ, Lee IK et al (2005a) Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol25:2488-2494.
89. Lee WJ, Song KH et al (2005b) Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun332:885-891.
90. Lee-Young RS, Griffee SR et al (2009) Skeletal muscle AMP-activated protein kinase is essential for the metabolic response to exercise in vivo. J Biol Chem284:23925-23934.
91. Lee-Young RS, Ayala JE et al (2010) Endothelial nitric oxide synthase is central to skeletal muscle metabolic regulation and enzymatic signaling during exercise in vivo. Am J Physiol Regul Integr Comp Physiol298:R1399-R1408.
92. Liao Y, Takashima S et al (2005) Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res67:705-713.
93. Lihn AS, Jessen N et al (2004) AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun316:853-858.
94. Lin HZ, Yang SQ et al (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med6:998-1003.
95. Lira VA, Soltow QA et al (2007) Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am J Physiol Endocrinol Metab293:E1062-E1068.
96. Lochhead PA, Salt IP et al (2000) 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes49:896-903.
97. Luo Z, Saha AK et al (2005) AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci26:69-76.
98. Lupi R, Del Guerra S et al (2002) Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 51(Suppl1):S134-S137.
99. Maeda N, Takahashi M et al (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes50:2094-2099.
100. Majithiya JB, Balaraman R (2006) Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci78:2615-2624.
101. Martin TL, Alquier T et al (2006) Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J Biol Chem281:18933-18941.
102. Matejkova O, Mustard KJ et al (2004) Possible involvement of AMP-activated protein kinase in obesity resistance induced by respiratory uncoupling in white fat. FEBS Lett569:245-248.
103. Maxwell AJ, Schauble E et al (1998) Limb blood flow during exercise is dependent on nitric oxide. Circulation98:369-374.
104. Merrill GF, Kurth EJ et al (1997) AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol273:E1107-E1112.
105. Michael LF, Wu Z et al (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA98:3820-3825.
106. Milne JC, Lambert PD et al (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature450:712-716.
107. Minokoshi Y, Haque MS et al (1999) Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes48:287-291.
108. Minokoshi Y, Kim YB et al (2002) Leptin stimulates fatty-acid oxidation by activating AMPactivated protein kinase. Nature415:339-343.
109. Minokoshi Y, Alquier T et al (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature428:569-574.
110. Mootha VK, Lindgren CM et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet34:267-273.
111. Moule SK, Denton RM (1998) The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett439:287-290.
112. Moynihan KA, Grimm AA et al (2005) Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab2:105-117.
113. Muoio DM, Seefeld K et al (1999) AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 338(Pt3):783-791.
114. Murry CE, Jennings RB et al (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation74:1124-1136.
115. Musi N, Fujii N et al (2001) AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes50:921-927.
116. Narkar VA, Downes M et al (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell134:405-415.
117. Nathan DM, Buse JB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia52:17-30.
118. Nawrocki AR, Rajala MW et al (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem281:2654-2660.
119. Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology37:1202-1219.
120. Nieto-Vazquez I, Fernandez-Veledo S et al (2008) Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes57:3211-3221.
121. Nishino Y, Miura T et al (2004) Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res61:610-619.
122. Nyblom HK, Sargsyan E et al (2008) AMP-activated protein kinase agonist dose dependently improves function and reduces apoptosis in glucotoxic beta-cells without changing triglyceride levels. J Mol Endocrinol41:187-194.
123. Orci L, Cook WS et al (2004) Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci USA101:2058-2063.
124. Ouchi N, Kihara S et al (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation103:1057-1063.
125. Pacholec M, Bleasdale JE et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem285:8340-8351.
126. Palanivel R, Sweeney G (2005) Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. FEBS Lett579:5049-5054.
127. Pan XR, Li GW et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care20:537-544.
128. Park H, Kaushik VK et al (2002) Coordinate regulation of malonyl-CoA decarboxylase, snglycerol- 3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem277:32571-32577.
129. Petersen KF, Befroy D et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science300:1140-1142.
130. Phillips SA, Ciaraldi TP et al (2003) Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes52:667-674.
131. Picard F, Kurtev M et al (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature429:771-776.
132. Pischon T, Girman CJ et al (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA291:1730-1737.
133. Pold R, Jensen LS et al (2005) Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes54:928-934.
134. Prentki M, Joly E et al (2002) Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 51(Suppl 3):S405-S413.
135. Rhodes CJ (2005) Type 2 diabetes-a matter of beta-cell life and death? Science307:380-384.
136. Riboulet-Chavey A, Diraison F et al (2008) Inhibition of AMP-activated protein kinase protects pancreatic beta-cells from cytokine-mediated apoptosis and CD8+ T-cell-induced cytotoxicity. Diabetes57:415-423.
137. Richards SK, Parton LE et al (2005) Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J Endocrinol187:225-235.
138. Roberts CK, Barnard RJ et al (1999) Acute exercise increases nitric oxide synthase activity in skeletal muscle. Am J Physiol277:E390-E394.
139. Rodgers JT, Puigserver P (2007) Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA104:12861-12866.
140. Rossmeisl M, Barbatelli G et al (2002) Expression of the uncoupling protein 1 from the aP2 gene promoter stimulates mitochondrial biogenesis in unilocular adipocytes in vivo. Eur J Biochem269:19-28.
141. Rubin LJ, Magliola L et al (2005) Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol 98:296-306.
142. Russell RR3rd, Li J et al (2004) AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest114:495-503.
143. Saha AK, Avilucea PR et al (2004) Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun314:580-585.
144. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature414:799-806.
145. Sanders MJ, Grondin PO et al (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J403:139-148.
146. Sell H, Dietze-Schroeder D et al (2006) Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochem Biophys Res Commun 343:700-706.
147. Shaw RJ, Lamia KA et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science310:1642-1646.
148. Shibata R, Ouchi N et al (2004a) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med10:1384-1389.
149. Shibata R, Ouchi N et al (2004b) Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 279:28670-28674.
150. Shibata R, Sato K et al (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med11:1096-1103.
151. Smith AC, Bruce CR et al (2005) AMP kinase activation with AICAR further increases fatty acid oxidation and blunts triacylglycerol hydrolysis in contracting rat soleus muscle. J Physiol565:547-553.
152. Song XM, Fiedler M et al (2002) 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 45:56-65.
153. Steinberg GR, Kemp BE (2009) AMPK in health and disease. Physiol Rev89:1025-1078.
154. Steinberg GR, Michell BJ et al (2006) Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab4:465-474.
155. Stephens TJ, Chen ZP et al (2002) Progressive increase in human skeletal muscle AMPKalpha2 activity and ACC phosphorylation during exercise. Am J Physiol Endocrinol Metab 282:E688-E694.
156. Stoppani J, Hildebrandt AL et al (2002) AMP-activated protein kinase activates transcription of the UCP3 and HKII genes in rat skeletal muscle. Am J Physiol Endocrinol Metab 283:E1239-E1248.
157. Sullivan JE, Brocklehurst KJ et al (1994) Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett353:33-36.
158. Sun C, Zhang F et al (2007) SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab6:307-319.
159. Sun G, Tarasov AI et al (2010) Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo. Diabetologia53(5):924-936.
160. Suter M, Riek U et al (2006) Dissecting the role of 50-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem281:32207-32216.
161. Suzuki A, Okamoto S et al (2007) Leptin stimulates fatty acid oxidation and peroxisome proliferator- activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Mol Cell Biol27:4317-4327.
162. Tomas E, Tsao TS et al (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA99:16309-16313.
163. Treebak JT, Birk JB et al (2007) AS160 phosphorylation is associated with activation of alpha2- beta2gamma1- but not alpha2beta2gamma3-AMPK trimeric complex in skeletal muscle during exercise in humans. Am J Physiol Endocrinol Metab292:E715-E722.
164. Tuomilehto J, Lindstrom J et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med344:1343-1350.
165. U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes44:1249-1258.
166. Um JH, Park SJ et al (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes59:554-563.
167. Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44:863-870.
168. Van Gaal LF, Mertens IL et al (2006) Mechanisms linking obesity with cardiovascular disease. Nature444:875-880.
169. Viana AY, Sakoda H et al (2006) Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res Clin Pract73:135-142.
170. Viollet B, Andreelli F et al (2003) Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans31:216-219.
171. Wang X, Zhou L et al (2007) Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Life Sci81:160-165.
172. Watt MJ, Holmes AG et al (2006) Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab290:E500-E508.
173. Weiss EP, Racette SB et al (2006) Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr84:1033-1042.
174. Willett WC, Dietz WH et al (1999) Guidelines for healthy weight. N Engl J Med341:427-434.
175. Winder WW, Hardie DG (1999) AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol277:E1-E10.
176. Winder WW, Holmes BF et al (2000) Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol88:2219-2226.
177. Wing RR, Goldstein MG et al (2001) Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care24:117-123.
178. Witters LA, Gao G et al (1994) Hepatic 5'-AMP-activated protein kinase: zonal distribution and relationship to acetyl-CoA carboxylase activity in varying nutritional states. Arch Biochem Biophys308:413-419.
179. Woods A, Azzout-Marniche D et al (2000) Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol20:6704-6711.
180. Xu A, Wang Y et al (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest112:91-100.
181. Yamauchi T, Kamon J et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med7:941-946.
182. Yamauchi T, Kamon J et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med8:1288-1295.
183. Yamauchi T, Kamon J et al (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem278:2461-2468.
184. Zang M, Xu S et al (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55:2180-2191.
185. Zarrinpashneh E, Carjaval K et al (2006) Role of the alpha2 isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol Heart Circ Physiol291(6):H2875-H2883.
186. Zhang J, Xie Z et al (2008) Identification of nitric oxide as an endogenous activator of the AMPactivated protein kinase in vascular endothelial cells. J Biol Chem283:27452-27461.
187. Zhou M, Lin BZ et al (2000) UCP-3 expression in skeletal muscle: effects of exercise, hypoxia, and AMP-activated protein kinase. Am J Physiol Endocrinol Metab279:E622-E629.
188. Zhou G, Myers R et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest108:1167-1174.
189. Zhou L, Wang X et al (2008) Berberine acutely inhibits insulin secretion from beta-cells through 30, 50-cyclic adenosine 50-monophosphate signaling pathway. Endocrinology149:4510-4518.
190. Zong H, Ren JM et al (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA99:15983-15987.
191. Zwetsloot KA, Westerkamp LM et al (2008) AMPK regulates basal skeletal muscle capillarization and VEGF expression, but is not necessary for the angiogenic response to exercise. J Physiol586:6021-6035.